About: admbbt

Boulder, Colorado - July 16, 2007 - Bolder BioTechnology, Inc. today announced that it has been awarded a $762,475 Phase II Small Business Innovation Research (SBIR) grant from the National Institute of Allergy and Infectious Diseases (NIAID) of The National Institutes of Health. The grant supports research to improve the pharmacological properties of a human protein,…

Boulder, Colorado - July 16, 2007 - Bolder BioTechnology, Inc. is pleased to announce that it has been granted patents 7,214,779 and 7,232,885 by the U.S. Patent and Trademark Office. Joe Cox, Company President commented "These patents broaden the scope of intellectual property protection for our long-acting, second generation granulocyte-macrophage colony-stimulating factor (GM-CSF) analog and granulocyte…

Boulder, Colorado - January 2, 2007 - Bolder BioTechnology, Inc. is pleased to announce that it has been granted patents 7,148,333 and 7,153,943 by the United States Patent and Trademark Office. Joe Cox, Company President said "These patents provide important intellectual property protection for our long-acting granulocyte-macrophage colony-stimulating factor (GM-CSF) analogs. GM-CSF is a human protein…

Boulder, Colorado - November 10, 2006 - Bolder BioTechnology, Inc. today announced that it has been awarded a $775,848 Phase II Small Business Innovation Research (SBIR) grant from the National Cancer Institute of The National Institutes of Health (NIH). The grant will be used to perform preclinical efficacy and pharmacology studies of the company's proprietary long-acting…